Nuvalent, INC Form 4 insider transactions

Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Nuvalent Inc. Director Matthew Shair sold 7,500 shares of Class A Common Stock for approximately $824,130 through a pre-arranged trading plan.

Deerfield Private Design Fund IV, L.P. and Deerfield Healthcare Innovations Fund, L.P. sold 742,574 shares of Nuvalent Class A Common Stock at $95.445 per share to underwriters as part of an over-allotment option in a public offering.

Nuvalent Inc.'s Chief Financial Officer, Alexandra Balcom, exercised stock options and subsequently sold a portion of her Class A Common Stock shares under a pre-arranged 10b5-1 trading plan.

Nuvalent's Chief Legal Officer, Deborah Ann Miller, exercised stock options and subsequently sold 24,200 shares of Class A Common Stock for over $2.5 million, pursuant to a pre-arranged 10b5-1 trading plan.

Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options and subsequently sold 4,000 shares of Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Nuvalent's Chief Legal Officer, Deborah Ann Miller, exercised stock options and subsequently sold an equivalent number of shares under a pre-arranged trading plan.

Nuvalent Director Matthew Shair sold over 60,000 shares of Class A Common Stock for approximately $6 million through a pre-arranged 10b5-1 trading plan.

Nuvalent's Chief Legal Officer, Deborah Ann Miller, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Nuvalent Inc.'s President and CEO, James Richard Porter, exercised stock options and subsequently sold a portion of his Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Nuvalent's Chief Legal Officer, Deborah Ann Miller, exercised stock options and subsequently sold a portion of the acquired Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Nuvalent's Chief Scientific Officer, Henry E. Pelish, exercised stock options and subsequently sold a portion of his Class A Common Stock shares under a pre-arranged 10b5-1 trading plan.

Nuvalent's Chief Financial Officer, Alexandra Balcom, sold 1,683 shares of Class A Common Stock for a weighted average price of $85.57 after exercising options, pursuant to a pre-arranged 10b5-1 trading plan.

Nuvalent CFO Alexandra Balcom executed planned stock option exercises and subsequent sales of Class A Common Stock totaling over $3.3 million under a Rule 10b5-1 trading plan.

Nuvalent's Chief Scientific Officer, Henry E. Pelish, executed pre-planned option exercises and subsequent sales of Class A Common Stock totaling 10,070 shares.

Nuvalent Inc.'s Chief Financial Officer, Alexandra Balcom, exercised stock options and subsequently sold a portion of the acquired Class A Common Stock on October 1, 2025, under a pre-arranged trading plan.

Nuvalent's Chief Financial Officer, Alexandra Balcom, executed planned sales of Class A Common Stock totaling 27,588 shares in late September 2025, following the exercise of stock options.

Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options and subsequently sold 4,000 shares of Class A Common Stock on September 29, 2025, under a pre-arranged 10b5-1 trading plan.

Nuvalent Inc.'s President and CEO, James Richard Porter, executed a pre-arranged 10b5-1 trading plan, exercising stock options and subsequently selling 27,000 shares of Class A Common Stock.

Nuvalent's Chief Scientific Officer, Henry E. Pelish, executed a series of pre-planned stock option exercises and subsequent sales of Class A Common Stock totaling 3,725 shares on September 10, 2025, under a Rule 10b5-1 trading plan.

Nuvalent's Chief Scientific Officer, Henry E. Pelish, exercised stock options to acquire 5,007 shares of Class A Common Stock.

Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options and subsequently sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

Nuvalent Inc.'s President and CEO, James Richard Porter, sold 27,000 shares of Class A Common Stock on August 15, 2025, following the exercise of stock options, as part of a pre-arranged Rule 10b5-1 trading plan.

Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 5,500 shares of Class A Common Stock for $74.85 per share after exercising options, as part of a pre-arranged Rule 10b5-1 trading plan.

Nuvalent's Chief Development Officer, Darlene Noci, executed a pre-planned transaction, exercising stock options and subsequently selling 4,000 shares of Class A Common Stock.

Nuvalent, Inc.'s Chief Financial Officer, Alexandra Balcom, executed pre-planned transactions, exercising stock options and selling Class A Common Stock on July 15 and 16, 2025, under a Rule 10b5-1 trading plan.

Nuvalent, Inc.'s President and CEO, James Richard Porter, exercised stock options and subsequently sold a portion of the acquired shares on July 15, 2025, under a pre-established Rule 10b5-1 trading plan.

Nuvalent, Inc.'s Chief Scientific Officer, Henry E. Pelish, reported a series of pre-planned stock sales and option exercises totaling a net decrease of 2,145 shares in his direct beneficial ownership of Class A Common Stock.

Nuvalent, Inc.'s Chief Financial Officer, Alexandra Balcom, sold 20,000 shares of Class A Common Stock for a weighted average price of $80.02 after exercising stock options at $18.93, as part of a Rule 10b5-1 trading plan.

Nuvalent, Inc.'s Chief Development Officer, Darlene Noci, exercised stock options and subsequently sold a portion of the acquired shares as part of a pre-scheduled Rule 10b5-1 trading plan.